From: Minimax and admissible adaptive two-stage designs in phase II clinical trials
π u | Simon | Minimax-EF | New adaptive design |
---|---|---|---|
0.2 | 0.716 | 0.402 | 0.674 |
0.3 | 0.666 | 0.582 | 0.417 |
0.4 | 0.913 | 0.921 | 0.527 |
0.5 | 0.661 | 0.589 | 0.589 |
0.6 | 0.647 | 0.554 | 0.597 |
0.7 | 0.946 | 0.949 | 0.579 |